INFORMATION DISCLOSURE CITATION (use Several Sheets if Necessary)

Group Art Unit:

(use Several Sheets if Neccosary)	1000		Mark Carter Control
U.S.	PATENT DOCUMEN	ne Class	Subcl. File Date
Exam. Initial Document No.	Date		

1		Date	Name		
m. Initial	Document No.	-			
					20/02
				CHRISTING DISK STREET	
	- Control of the state of the s	NTS (Including Auth	or Title, Date, Per	tinent Pages, etc.	for the
	OTHER DOCUME	NTS (Including Aut	tergoted expres	sion of the HSVtk	gene loi trie
A second second	Ader	novirus-mediated tiss	ue-targeted expres	(1999)	
Ande	OTHER DOCUME erson, L.M. et al., "Ader eatment of breast cancer ony, B. et al., "Overexpand on the cancer," Int. J. Cancer,	er," Gene Therapy, V	Ol. 6, pp. 004 00	n factor elF-4E in	breast carcinoma
· tr	eatment of broad	4 11 - motor	ncodene-lianolario	,,, ,,,,,	
Anth	iony, B. et al., "Overexpell lines," Int.J.Cancer, ey, K. et al., "An adeno	vol. 65, pp. 858-863	(1995)	treatment of ischi	aemic disease and
// C	ell lines, inco-	· · · · · · · · · · · · · · · · · · ·	hy hypoxia ioi iiic		
Bin	ey, K. et al., "An adeno cancer," Gene Therapy	vial 6 pp. 1721-172	7 (1999).	t Dischem	Cell Biol., vol. 31,
ν	ancel, Geno		cancer connection	,	
Clo	mens M.J. et al., "Irali	Islational		h	adder cancer and
p J Cle	pp. 1-23 (1999) ew, J.P. et al., Eukaryot its correlation with vas	forter 4E	in superficial and r	nuscle invasive bi	oression," Br. J.
	IP et al. Eukaryot	tic initiation factor-4E	wth factor expressi	on and tumour pro	igressio
Cre	its correlation with vas Cancer, vol. 82, pp. 16 Benedetti, A. et al., "e	cular endotheliai gio			f malignancies."
P	Concor VOL 04, PP. 15		ita nassinie	fole in progress	1 of mangranes
	Duradotti A et al., "e	IF4E expression in the	31 nn 59-72 (19	99)	r Cuinida
	Benedetti, A. et al., "e Int. J. of Biochemistry Fatta, R.J. et al., "A Ci	and Cell Biology, voi	. Jr, pp.	Translational Co	ntrol of a Suicide
Z	Int. J. Of Diese	ancer Gene Therapy	Approach Throas		
91/ D					
7	Gene, Submitte	Fukaryotic Translati	on initiation Factor	ubmitted to the Gr	aduate Faculty of
D	Fatta, R.J. et al., "A Ci Gene," submitted to N eFatta, Robert J., "The and as a Target for C	ancer Gene Therap)	," a Dissertation, e	and Mechanical	College, Catalogues
Ql/	Medical Center of Lo and placed on the sh DeFatta, R.J. et al., "Se	elf on March 20, 200	Dagod on	Translational Con	trol of a Suicide
	and placed strat "Se	lective Killing of Can	cer Cells based on		
Qe 5	DeFatta, R.J. et al., "Se Gene," submitted to Na Goldfarb, R.H. et al., "T	ture Medicine, July 9	, 2001	olished metastase	s and inhibitors of
Xe C	Gene, Submitted to	ture Medicine, July 9 herapeutic agents fo preclinical and clinica	r treatment of estat	t Opinion in Oncol	ogy, vol. 4, pp. 1130
	Goldfarb, R.H. et al.,	reclinical and clinica	progress, Current		
الرم	metastatic spread.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		n Journal of Cano	er, vol. 35(6), pp.
Y	A1 (1992)	for	concer " Europea	II Journa.	
11	Gomez-Navarro, J. et a 2039-2057 (1999) Hall, S.J. et al., "Coope	ai., Co		Listian and aden	ovirus-mediated her
ge	2039-2057 (1999)	- estive therapeutic ef	fects of androgen	apiation and additi	prostate cancer, "
0	Hall, S.J. et al., "Coop	erative therapedas	d ganciclovir thera	DA III EVDEULIOUS	
00/	simplex virus thym	erative therapeutic ef idine kinase gene an any, vol. 6, pp. 54-6	3 (1999).	- atoto: Δ	phase I clinical trial,
7	Cancer Gene The	up)i	r adenocarcinoma	of the prostate. A	p
001	Herman, J.R. et al.,"Ir	situ gene illerapy lo	9-1249 (1999)		
40	Human Gene The	n situ gene therapy to rapy, vol. 10, pp. 123			
L'			DATE	CONSIDERED	
	The state of the s		D/ tit	_	

Human Gene Therapy, To	
	DATE CONSIDERED
EXAMINER	4-16-0-
1	dered, whether or not citation is in conformance with MPEP 609; the citation if not in conformance and not considered. Include the citation if not in conformance and not considered.
* EXAMINER: Initial if citation consider	dered, whether or not citation is in conformance with the citation if not in conformance and not considered. Include the citation if not in conformance and not considered.

draw a line through the citation if not in conformance and not considered. Include * EXAMINER: copy of this form with next communication to applicant.

Form PTO-1449 (Rev. 2-97 by App.)

gr

d

Q.

U.S. Department of Commerce Patent and Trademark Office

Att'v Docket No. Serial No. Annlicant:

00508 DeBenedetti na/

INFORMATION DISCLOSURE CITATION

(use Several Sheets if Necessary)

Filing Date Group Art Unit: Arrigo DeBenedetti et al. July 26, 2001

and the second	TO SERVICE SER	U.S. PATENT D	OCUMENTS	4 6 10 00 C 44 C	operation.	File Date
N. 10 C. C.	Document No.	Date	Name	Class	Subcl.	THE DUIC
Exam. Initial	Document No.					
						1

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Kaloss, M. et al., "Distribution of retroviral vectors and vector producer cells using two routes of administration in rats," Gene Therapy, vol. 6, pp. 1389-1396 (1999)

Kerekatte, V.V. et al., "The proto-oncogene/ translation initiation factor eIF4E: a survey of its expression in breast carcinomas, Int. J. Cancer., vol. 64, pp. 27-31 (1995)

Kevil, C. et al., "Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG

and AUG codons for translation initiation, Oncogene, vol. 11, pp. 2339-2348 (1995) Kevil, C. et al., "Translational regulation of Vascular Permeability Factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis," Int. J. Cancer, vol. 65, pp. 785-790 (1998)

Klatzmann, D. et al., "A Phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent metastatic melanoma," Human Gene Therapy, vol. 9,

Koromilas, A.E. et al., "mRNAs containing extensive secondary structure in their 5' non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E," The EMBO Journal, vol. 11, pp.

Long, Z. et al., "Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy, Human Gene Therapy, vol. 10, pp.:733-40 (1999)

Miyagi, Y. et al., "Elevated levels of eukaryotic initiation factor eIF-4E mRNA in a broad spectrum of transformed cell lines," Cancer Letters, vol. 91, pp. 247-252 (1995)

Nathan, C.O. et al., "Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer," Oncogene, vol. 15, pp. 579-584 (1997)

Ramesh, R. et al., "In vivo analysis of the "bystander effect": a cytokine cascade," Experimental Hematology, vol. 24, pp. 829-838 (1996)

Rosenwald, I.B., "Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2alpha in transformed cells," Cancer Letters, vol. 102, pp. 113-23 (1996) Rosenwald, I.B. et al., "Upregulation of protein synthesis initiation factor eIF4E is an early event during

colon carcinogenesis," Oncogene, vol.18, pp. 2507-2517 (1999) Roth, J.A. et al., "Gene therapy for cancer: what have we done and where are we going?" Journal of

the National Cancer Institute, vol. 89(1), p. 21-39 (1997) Scott, P.A.E. et al., "Differential expression of vascular endothelial growth factor mRNA versus protein

isoforms expression in human breast cancer and relationship to eIF4E," British. J. Cancer, vol. 77, pp. 2120-2128 (1998)

DATE CONSIDERED EXAMINER 4-16-02

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw a line through the citation if not in conformance and not considered. Include * EXAMINER: copy of this form with next communication to applicant.